4//SEC Filing
Glickman Mark A 4
Accession 0001209191-22-060586
CIK 0000025743other
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 7:38 PM ET
Size
9.3 KB
Accession
0001209191-22-060586
Insider Transaction Report
Form 4
Glickman Mark A
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2022-12-06+1,734→ 1,734 total - Exercise/Conversion
Restricted Stock Units
2022-12-06−1,734→ 3,466 totalExercise: $0.00→ Common Stock (1,734 underlying) - Sale
Common Stock
2022-12-06$4.92/sh−440$2,165→ 1,294 total
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs).
- [F2]The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
- [F3]The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.
Documents
Issuer
TherapeuticsMD, Inc.
CIK 0000025743
Entity typeother
Related Parties
1- filerCIK 0001441461
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 7:38 PM ET
- Size
- 9.3 KB